English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Figure 1. Chemical structure of Ivabradine Hydrochloride Recently, ivabradine was approved by the U. S. Food and Drug Administration (USFDA) as a heart-rate-lowering agent in 2015. Ivabradine is the first drug with a novel mechanism of action acting by specifically and selectively inhibiting the cardiac pacemaker current (If), a mixed sodium-potassium inward current that controls the spontaneous diastolic depolarization in the sinoatrial (SA) node and hence regulates the heart rate (Sabharwal and Kukin, 2015). The molecular channel of Ivabradine HCl belongs to the HCN family. If ion current flow is disrupts by the inhibition of this channel, thereby prolonging diastolic depolarization, slowing firing in the SA node, and eventually reducing the heart rate (Psotka and Teerlink, 2016). The Cardiac effects of Ivabradine are specific to the SA node, and the drug has no effect on blood pressure, intracardiac conduction, ventricular repolarization, myocardial contractility (Tse and Mazzola, 2015).

asian journal of pharmacy and pharmacology

Quantitative determination and validation of novel derivative spectrophotometric method for estimation of Ivabradine hydrochloride in bulk and marketed formulation